LEGN: רווח נקי למניה (EPS TTM) Legend Biotech Inc.

Legend Biotech strictly adheres to ESG standards when handling biomaterials, optimizing its cold chain logistics. Business growth relies on scaling CAR-T therapy production, rendering revenues independent of macro cycles. However, high production costs and the relationship with J&J create risks. The 12-month rolling earnings per share history demonstrates yield dynamics, where -0.51 expresses the metric's current value.

Investors are assessing the potential of Legend Biotech (LEGN) through the business's ability to generate real income per share, which determines the asset's fundamental value. This metric calculates the annual net income per share, adjusted for the total volume of shares, reflecting the commercialization efficiency of Carvykti and the control of R&D expenses. By analyzing the company's net income per share over 12 months, one can identify capital consolidation phases prior to the potential scaling of the therapy.